July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Sarah Premji Shares ASCENT-04 Trial Outcomes in First-Line TNBC Treatment at ASCO 2025
Jun 1, 2025, 16:02

Sarah Premji Shares ASCENT-04 Trial Outcomes in First-Line TNBC Treatment at ASCO 2025

Sarah Premji, Clinical Oncology Fellow at Mayo Clinic, posted on X:

“ASCENT-04 met TNBC evaluating use of sacituzumab +pembro vs chemo + pembro in the 1st line.
  • baseline 50% lung 25% liver mets
  •  11.2 mo vs 7.8 mo imp in mPFS
  •  Longer DOR 16.5 mo vs 9.2 mo and higher ORR
  •  no inc irAE
New potential SOC!”

Sarah Premji Shares ASCENT-04 Trial Outcomes in First-Line TNBC Treatment at ASCO 2025

More posts featuring ASCO25.